Is Nutex Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a low P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. In comparison, Fulgent Genetics, Inc. has a significantly negative P/E ratio of -21.28, while Talkspace, Inc. is considered expensive with a P/E of 156.07, highlighting Nutex's relative value.
Nutex Health has demonstrated exceptional stock performance, with a year-to-date return of 199.26%, vastly outperforming the S&P 500's 13.30% during the same period. This strong return reinforces the notion that Nutex Health is undervalued in the current market context.